UTG 3Q 2026: Revenue $14.86M, EPS $2.19 — 10-Q Summary

UTG reported a 14.3% revenue decline to $14.86M and a 30% drop in net income to $6.89M, with lower net investment gains cited as a key factor. Net investment income rose to $4.9M, while fair-value gains on equity securities fell to $8.7M. The company also noted a potential $18M gain from a land sale, though completion is uncertain.

Original reporting
Published Nov 12, 2026, 7:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 7:06 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
UTG 3Q 2026: Revenue $14.86M, EPS $2.19 — 10-Q Summary — source image
Decision brief

The 30-second read

$UTGNBearishLow
01

Why it matters

The earnings miss is likely to depress the stock in the short term, though the pending land sale could provide a catalyst if completed.

02

Market read

Primary micro‑cap earnings disclosure with modest negative impact; limited relevance beyond niche investors.

03

What to watch

The increase in net investment income and potential $18M real‑estate gain are not reflected in the current earnings numbers.

Relevance 6/10Novelty 6/10Timing: after-hours reaction

Background

UTG Inc. (OTC: UTGN) reported its Q3 2026 results via a 10‑Q filing, highlighting lower revenue and earnings but higher investment income and a pending real‑estate sale.

Company-level read

Ticker impact

$UTGNBearishMedium confidence
Context

UTG Inc. filed its 10‑Q reporting Q3 2026 revenue of $14.86M and EPS of $2.19, a 14.3% revenue decline and 30% EPS drop versus the prior year.

Expected impact

likely pressure as the market prices in the revenue and earnings decline

Evidence & confidence

Micro‑cap earnings miss with no offsetting guidance; investors typically react negatively to lower revenue and EPS.

Market effects

Minimal; the filing reflects weakness in the niche investment‑income segment.

Limited to investors tracking micro‑caps and specialty finance stocks.

Low; no broader market impact.

Counterpoint

If the land sale proceeds materialize, the company could swing to profitability, offering a contrarian upside.

Key entities

  • UTG Inc.

    Micro‑cap investment‑income firm reporting Q3 2026 results.

Related articles

$PTHSMed

Pelthos (PTHS) Q3 2026 Earnings Call Transcript

Pelthos (PTHS) reported Q3 2026 net revenue of $15.2M, up 114% YoY, with Zelsuvmi treating 31,000 patients. Formulary coverage expanded to 70% of commercial lives. The company announced a deal with Castle Creek Biosciences, aiming to leverage synergies in dermatology and cell/gene therapy markets. Xepi and Xeglyze launches are planned for 2027.

$BMNRMedAI 8/10

Bitmine’s ($BMNR) $6.3 Billion Loss Highlights Overall Risks for Strategy ($MSTR) and Other Treasury Firms as MSCI Tightens Rules

Bitmine Immersion Technologies (BMNR) reported a $6.3B net loss for fiscal 2026, driven by $6.23B in unrealized losses on digital-asset holdings, primarily ether. The company held 5.9M ether tokens and 211 bitcoin at year-end. Operating revenue was $125M, with staking contributing 97%. MSCI's updated index rules may impact BMNR and other crypto-focused treasury firms, including Strategy (MSTR).

HighAI 8/10

Merck KGaA Earnings Call Signals Stronger Growth Ahead

Merck KGaA (MKKGY) reported Q3 earnings with accelerated growth, raised full-year guidance, and announced strategic investments. Key highlights include 5.1% organic sales growth, EUR 1.66B operating cash flow, and plans to acquire Silence Therapeutics. Management emphasized growth in biomanufacturing, semiconductors, and rare diseases, while noting Mavenclad's declining sales and softer demand in consumer electronics.

$EZPWMed

EZCORP shares fall despite record Q4 as costs overshadow beat

EZCORP (EZPW) reported Q4 revenue of $447M, beating estimates, with full-year revenue up 30% to $1.7B and adjusted EBITDA up 47% to $277M. Despite strong results, shares fell 4.13% due to concerns about labor costs and integration timing in Latin America. Insiders filed SEC disclosures, and short-sale activity increased ahead of the earnings release.

$FLNTMed

What Fluent (FLNT) Said on Its Q3 Earnings Call

Fluent (FLNT) reported a Q3 net loss of $3.1M, improved from last year. Adjusted EBITDA loss narrowed to $43K, with positive EBITDA expected in Q4. Cash decreased to $11.4M, with $31.5M in short-term debt. The company guided toward high 20% gross margins and potential double-digit revenue growth in 2027, while testing in-store and loyalty offerings.